The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group announced that its HER2-targeting antibody-drug conjugate, JSKN003, has received Breakthrough Therapy Designation in China for treating platinum-resistant ovarian cancer. This designation is expected to expedite the drug’s development and review process, potentially positioning it as the first anti-HER2 treatment for this condition, offering significant clinical benefits and a favorable safety profile.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development and production of innovative drugs. Its primary products include antibody-drug conjugates and other therapies targeting various cancers, with a market focus on addressing significant unmet clinical needs.
YTD Price Performance: 6.27%
Average Trading Volume: 4,371
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.16B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.